Attractively, a recent study by Zhang et al. has shown that more than 50% of relapsed pediatric ALL patients have RAS pathway mutations (KRAS, NRAS, NF1, EPOR), further consolidating the role of RAS mutations in relapsed ALL. Here, NF1 is linked to acute lymphoblastic leukemia.